Umedica Laboratories Private Limited — Nifedipine Exporter Profile
Indian Pharmaceutical Exporter · #9 for Nifedipine · $867.8K export value · DGFT Verified
Umedica Laboratories Private Limited is the #9 Indian exporter of Nifedipine with $867.8K in export value and 28 verified shipments. Umedica Laboratories Private Limited holds a 2.9% market share in Nifedipine exports across 4 countries. The company exports 11 pharmaceutical products worth $32.2M across 8 therapeutic categories.
Umedica Laboratories Private Limited — Nifedipine Export Profile: Buyers & Destinations
Where Does Umedica Laboratories Private Limited Export Nifedipine?
| Country | Value | Shipments | Share |
|---|---|---|---|
| TANZANIA | $333.9K | 9 | 47.0% |
| GHANA | $293.0K | 13 | 41.2% |
| MOZAMBIQUE | $73.9K | 6 | 10.4% |
| ZAMBIA | $9.8K | 1 | 1.4% |
Umedica Laboratories Private Limited exports Nifedipine to 4 countries. The largest destination is TANZANIA accounting for 47.0% of Umedica Laboratories Private Limited's Nifedipine shipments, followed by GHANA (41.2%) and MOZAMBIQUE (10.4%). These destinations reflect Umedica Laboratories Private Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Nifedipine from Umedica Laboratories Private Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| P & G PHARMACEUTICALS LTD | TANZANIA | $150.0K | 3 |
| M/S,SALOM PHARMACY LIMITED, | GHANA | $146.2K | 8 |
| PRIME PHARMACEUTICALS LTD | TANZANIA | $144.0K | 6 |
| M/S SALOM PHARMACY LIMITED | GHANA | $79.3K | 3 |
| M/S.SALOM PHARMACY LIMITED, | GHANA | $67.6K | 2 |
| PRIME PHARMACEUTICALS LIMITED | TANZANIA | $39.5K | 1 |
| KARMA PHARMACEUTICALS LTD. | TANZANIA | $34.8K | 1 |
| INTERMED | TANZANIA | $24.6K | 2 |
| KARMA PHARMACEUTICALS LTD, | ZAMBIA | $9.8K | 1 |
| INTERMED P O BOX | MOZAMBIQUE | $8.0K | 1 |
Umedica Laboratories Private Limited supplies Nifedipine to 11 buyers globally. The largest buyer is P & G PHARMACEUTICALS LTD (TANZANIA), followed by M/S,SALOM PHARMACY LIMITED, (GHANA) and PRIME PHARMACEUTICALS LTD (TANZANIA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Nifedipine Export Value and How Much Does Umedica Laboratories Private Limited Contribute?
India exported $22.3M worth of Nifedipine through 2,751 shipments from 331 suppliers to 117 countries, serving 666 buyers globally. Umedica Laboratories Private Limited contributes $867.8K to this total, accounting for 2.9% of India's Nifedipine exports. Umedica Laboratories Private Limited ships Nifedipine to 4 countries through 11 buyers.
What Is the Average Shipment Value for Umedica Laboratories Private Limited's Nifedipine Exports?
Umedica Laboratories Private Limited's average Nifedipine shipment value is $31.0K per consignment, based on 28 shipments totaling $867.8K. The largest destination is TANZANIA (47.0% of Umedica Laboratories Private Limited's Nifedipine exports).
How Does Umedica Laboratories Private Limited Compare to Other Indian Nifedipine Exporters?
Umedica Laboratories Private Limited ranks #9 among 331 Indian Nifedipine exporters with a 2.9% market share. The top 3 exporters are CIPLA LIMITED ($5.2M), ALKEM LABORATORIES LIMITED ($3.6M), TORRENT PHARMACEUTICALS LTD ($3.4M). Umedica Laboratories Private Limited processed 28 shipments to 4 destination countries.
What Nifedipine Formulations Does Umedica Laboratories Private Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| NIFEDIPINE RETARD 20 (NIFEDIPINE EXTENDED RELEASE TABLETS USP 20MG.)(BOX OF 10X10 TABLETS) | $167.3K | 4 |
| NIFEDIPINE RETARD 20 (NIFEDIPINE EXTENDED RELEASE TABLETS USP 20MG.) (BOX OF 10X10 TABLETS) | $91.6K | 4 |
| NIFEDIPINE RETARD 20MG (NIFEDIPINE EXTE | $85.7K | 3 |
| NIFEDIPINE RETARD 20 (NIFEDIPINE EXTENDE | $52.4K | 2 |
| NIFEDIPINE RETARD 20MG (NIFEDIPINEEXTENDED RELEASE TABLETS 20MG ) (BOX OF 10X10 TABLETS) | $50.0K | 1 |
| NIFEDIPINE RETARD 20MG (NIFEDIPINE EXTENDED RELEASE TABLETS 20MG ) (BOX OF 10X10 TABLETS) | $48.9K | 1 |
| NIFEDIPINE RETARD 20MG (NIFEDIPINE EXTENDED RELEASE TABLETS 20MG ) (BOX OF 3X10 TABLETS) | $48.0K | 3 |
| NIFEDIPINE RETARD 20MG (NIFEDIPINE EXTEN | $47.4K | 4 |
| NIFEDIPINE RETARD 20 NIFEDIPINE EXTEND | $39.5K | 1 |
| NIFEDIPINE RETARD 20(NIFEDIPINE EXTENDED RELEASE TABLETS USP 20MG.) (BOX OF 10X10 TABLETS) | $34.8K | 1 |
Umedica Laboratories Private Limited exports 15 distinct Nifedipine formulations including tablets, capsules, syrups, and combination drugs. The top formulation is NIFEDIPINE RETARD 20 (NIFEDIPINE EXTENDED RELEASE TABLETS US with 4 shipments worth $167.3K.
How Does Umedica Laboratories Private Limited Compare to Nearest Nifedipine Exporters?
Exporters ranked immediately above and below #9 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 7 | LINCOLN PHARMACEUTICALS LTD | $995.2K | 29 | 8 | $34.3K |
| 8 | MARKSANS PHARMA LIMITED | $949.0K | 45 | 1 | $21.1K |
| 9 | UMEDICA LABORATORIES PRIVATE LIMITED ★ | $867.8K | 28 | 4 | $31.0K |
| 10 | TORRENT PHARMACEUTICALS LIMITED | $678.0K | 31 | 7 | $21.9K |
| 11 | MEDWISE OVERSEAS PRIVATE LIMITED | $646.9K | 28 | 3 | $23.1K |
Umedica Laboratories Private Limited ranks #9 among 331 Indian Nifedipine exporters. Average shipment value of $31.0K compared to the market average of $67.5K. The closest competitors by value are LINCOLN PHARMACEUTICALS LTD and MARKSANS PHARMA LIMITED.
Which Indian Ports Ship Nifedipine Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 407 | 14.8% |
| NHAVA SHEVA SEA (INNSA1) | 352 | 12.8% |
| SAHAR AIR CARGO ACC (INBOM4) | 310 | 11.3% |
| JNPT/ NHAVA SHEVA SEA | 194 | 7.1% |
| JNPT | 172 | 6.3% |
| DELHI AIR | 147 | 5.3% |
| DELHI AIR CARGO ACC (INDEL4) | 145 | 5.3% |
| Bombay Air | 82 | 3.0% |
What Other Cardiovascular Products Does Umedica Laboratories Private Limited Export?
Umedica Laboratories Private Limited also exports these cardiovascular products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on Umedica Laboratories Private Limited's Nifedipine Exports
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Umedica Laboratories. The Israel-Iran conflict has led to disruptions in Middle East trade routes, particularly affecting the Red Sea shipping lanes. Major shipping lines have imposed 'Emergency Risk Surcharges' ranging from $250 to $500 per TEU, effectively increasing the cost of exporting goods through these routes. This escalation in shipping costs can erode profit margins and necessitate strategic adjustments in logistics and pricing strategies. (sgeexport.com)
Conversely, the US-China trade tensions have prompted the United States to seek alternative sources for pharmaceuticals, potentially benefiting Indian exporters. However, the imposition of tariffs on Indian goods by the US, including a 25% tariff announced in 2025, poses a significant challenge. This tariff could lead to increased costs for Indian pharmaceutical products in the US market, potentially affecting demand and profitability. (en.wikipedia.org)
The recent India-European Union Free Trade Agreement (FTA), signed in January 2026, offers a promising avenue for Umedica. The FTA eliminates tariffs on Indian pharmaceutical exports to the EU, providing a competitive advantage and facilitating market expansion. This agreement is expected to open a market worth $572.3 billion for Indian pharmaceutical and MedTech exports to Europe from 2027 onward. (mordorintelligence.com)
Umedica Laboratories Private Limited — Regulatory Compliance & Quality Standards
Compliance with international regulatory standards is paramount for Indian pharmaceutical exporters. The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have stringent Good Manufacturing Practice (GMP) requirements. Historically, non-compliance has led to import bans and reputational damage for Indian firms. For instance, in 2013, the FDA banned imports from certain Indian pharmaceutical companies due to GMP violations, highlighting the critical importance of adherence to quality standards. (comcec.org)
While specific regulatory events concerning Umedica Laboratories are not detailed in the available data, the company's sustained export performance suggests a commitment to maintaining high-quality standards and compliance with international regulations. Continuous investment in quality control systems and regulatory compliance is essential to navigate the evolving landscape and to capitalize on global market opportunities.
About Umedica Laboratories Private Limited
Umedica Laboratories Private Limited exports 11 products worth $32.2M. Beyond Nifedipine, top products include Atorvastatin, Calcium, Rosuvastatin, Celecoxib, Hydrocortisone. View the complete Umedica Laboratories Private Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Nifedipine — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Nifedipine shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Umedica Laboratories Private Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 29 individual customs records matching Umedica Laboratories Private Limited exporting Nifedipine, covering 15 formulations to 4 countries via 11 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 117+ countries, 666+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Nifedipine Export Data from Umedica Laboratories Private Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Umedica Laboratories Private Limited's Nifedipine exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Umedica Laboratories Private Limited
Full Company Profile →
11 products · $32.2M total trade · 8 categories
Nifedipine Stats
Company Overview
Top Products by Umedica Laboratories Private Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Umedica Laboratories Private Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Nifedipine. For current shipment-level data, contact TransData Nexus.